Skip to main content
NVDA-0.12%AAPL+0.03%MSFT+0.11%GOOGL+1.19%AMZN+0.08%TSM+2.95%SPCX+1.14%AVGO+4.00%TSLA-0.27%META-0.05%LLY+0.22%BRK-B-1.02%MU-0.39%SKHY+1.92%WMT-0.81%AMD+5.45%JPM+0.52%V-0.57%XOM-2.53%JNJ+0.91%ASMLa+2.80%MA-0.59%ABBV-0.10%INTC+3.61%1398.HK+2.15%CVX-1.59%0700.HK-0.31%CSCO+1.03%COST-1.30%ORCL+3.55%KO-1.64%UNH-0.08%PG-0.45%BAC+0.32%1816.HK+1.32%3988.HK+0.66%CAT+3.06%DELL+7.38%HD-0.28%PM+0.37%0857.HK-0.98%AMAT+2.15%AP2d+2.18%0939.HK+0.81%GE+3.20%1288.HK+0.60%LRCX+1.41%NVS+1.98%0005.HK-5.56%MS+1.91%USDJPY+0.69%EURUSD-0.67%USDMXN+0.57%NZDMXN+0.57%AUDJPY+0.54%AUDDKK+0.53%EURAUD-0.52%USDCHF+0.52%GBPUSD-0.50%EURZAR-0.47%EURCNH-0.46%EURHKD-0.43%EURSEK-0.43%USDDKK+0.42%GBPTRY+0.41%EURSGD-0.38%AUDCHF+0.38%CADJPY+0.36%EURNZD-0.35%USDCAD+0.35%NZDJPY+0.35%GBPAUD-0.35%NZDUSD-0.33%GBPHKD+0.32%GBPZAR-0.31%EURCAD-0.31%USDPLN+0.30%GBPMXN-0.28%EURNOK-0.28%AUDNOK+0.25%SGDJPY+0.25%GBPSGD-0.23%CHFSEK-0.20%AUDCAD+0.19%CHFJPY+0.19%GBPJPY+0.18%NZDCHF+0.18%AUDNZD+0.17%CADCHF+0.17%USDTRY+0.17%GBPCAD-0.17%EURGBP-0.17%EURCHF-0.17%USDILS+0.16%GBPNZD-0.16%AUDUSD-0.15%AUDSGD+0.15%CHFSGD-0.15%NOKJPY+0.15%USDNOK+0.14%EURPLN-0.12%EURCZK-0.06%CHFNOK-0.04%USDZAR-0.04%USDCOP-0.04%USDCNH-0.04%USDHKD+0.04%USDSGD+0.04%NZDSGD+0.03%EURJPY+0.03%USDTHB+0.01%PLNJPY-0.01%USDSEK-0.01%GBPCHF+0.01%NZDCAD0.00%EURDKK0.00%HG1+1.70%XNGUSD+1.25%XAUUSD+1.06%GAUUSD+1.06%USOIL-0.96%XAGUSD+0.89%GAGUSD+0.89%XPTUSD+0.82%UKOIL-0.59%SUGAR0.00%COTTON0.00%W10.00%BTCUSD+0.79%ETHUSD+23.96%USDTUSD+0.06%XRPUSD+14.74%SOLUSD+17.47%TRXUSDT+0.70%ZECUSDT+5.22%DOGEUSD+20.65%XMRUSDT+1.12%LINKUSD+25.58%BCHUSDT+3.22%XLMUSD+0.43%UNIUSD-1.20%LTCUSD+17.89%SUIUSD+0.81%HBARUSDT-1.77%TONUSD+41.71%TAOUSDT+0.73%AAVEUSD-2.56%DOTUSDT-1.68%ICPUSDT-2.13%ONDOUSDT0.00%WLDUSDT+0.37%ARBUSDT-0.99%JUPUSDT+0.30%INJUSDT+0.21%ATOMUSDT-1.25%STXUSDT-1.40%TIAUSDT-0.88%PYTHUSDT-3.02%FETUSDT+3.01%SEIUSDT+0.54%IMXUSDT-1.38%GRTUSDT+0.90%OPUSDT-1.09%WIFUSDT-0.61%IOTAUSDT-0.07%POLUSDT+0.51%AXSUSDT+0.51%EOSUSDT+0.64%FARTCOINUSDT+1.95%DYDXUSDT+2.98%GALAUSDT+0.98%ORDIUSDT+2.19%RONINUSDT+1.89%NOTUSDT+1.92%NVDA-0.12%AAPL+0.03%MSFT+0.11%GOOGL+1.19%AMZN+0.08%TSM+2.95%SPCX+1.14%AVGO+4.00%TSLA-0.27%META-0.05%LLY+0.22%BRK-B-1.02%MU-0.39%SKHY+1.92%WMT-0.81%AMD+5.45%JPM+0.52%V-0.57%XOM-2.53%JNJ+0.91%ASMLa+2.80%MA-0.59%ABBV-0.10%INTC+3.61%1398.HK+2.15%CVX-1.59%0700.HK-0.31%CSCO+1.03%COST-1.30%ORCL+3.55%KO-1.64%UNH-0.08%PG-0.45%BAC+0.32%1816.HK+1.32%3988.HK+0.66%CAT+3.06%DELL+7.38%HD-0.28%PM+0.37%0857.HK-0.98%AMAT+2.15%AP2d+2.18%0939.HK+0.81%GE+3.20%1288.HK+0.60%LRCX+1.41%NVS+1.98%0005.HK-5.56%MS+1.91%USDJPY+0.69%EURUSD-0.67%USDMXN+0.57%NZDMXN+0.57%AUDJPY+0.54%AUDDKK+0.53%EURAUD-0.52%USDCHF+0.52%GBPUSD-0.50%EURZAR-0.47%EURCNH-0.46%EURHKD-0.43%EURSEK-0.43%USDDKK+0.42%GBPTRY+0.41%EURSGD-0.38%AUDCHF+0.38%CADJPY+0.36%EURNZD-0.35%USDCAD+0.35%NZDJPY+0.35%GBPAUD-0.35%NZDUSD-0.33%GBPHKD+0.32%GBPZAR-0.31%EURCAD-0.31%USDPLN+0.30%GBPMXN-0.28%EURNOK-0.28%AUDNOK+0.25%SGDJPY+0.25%GBPSGD-0.23%CHFSEK-0.20%AUDCAD+0.19%CHFJPY+0.19%GBPJPY+0.18%NZDCHF+0.18%AUDNZD+0.17%CADCHF+0.17%USDTRY+0.17%GBPCAD-0.17%EURGBP-0.17%EURCHF-0.17%USDILS+0.16%GBPNZD-0.16%AUDUSD-0.15%AUDSGD+0.15%CHFSGD-0.15%NOKJPY+0.15%USDNOK+0.14%EURPLN-0.12%EURCZK-0.06%CHFNOK-0.04%USDZAR-0.04%USDCOP-0.04%USDCNH-0.04%USDHKD+0.04%USDSGD+0.04%NZDSGD+0.03%EURJPY+0.03%USDTHB+0.01%PLNJPY-0.01%USDSEK-0.01%GBPCHF+0.01%NZDCAD0.00%EURDKK0.00%HG1+1.70%XNGUSD+1.25%XAUUSD+1.06%GAUUSD+1.06%USOIL-0.96%XAGUSD+0.89%GAGUSD+0.89%XPTUSD+0.82%UKOIL-0.59%SUGAR0.00%COTTON0.00%W10.00%BTCUSD+0.79%ETHUSD+23.96%USDTUSD+0.06%XRPUSD+14.74%SOLUSD+17.47%TRXUSDT+0.70%ZECUSDT+5.22%DOGEUSD+20.65%XMRUSDT+1.12%LINKUSD+25.58%BCHUSDT+3.22%XLMUSD+0.43%UNIUSD-1.20%LTCUSD+17.89%SUIUSD+0.81%HBARUSDT-1.77%TONUSD+41.71%TAOUSDT+0.73%AAVEUSD-2.56%DOTUSDT-1.68%ICPUSDT-2.13%ONDOUSDT0.00%WLDUSDT+0.37%ARBUSDT-0.99%JUPUSDT+0.30%INJUSDT+0.21%ATOMUSDT-1.25%STXUSDT-1.40%TIAUSDT-0.88%PYTHUSDT-3.02%FETUSDT+3.01%SEIUSDT+0.54%IMXUSDT-1.38%GRTUSDT+0.90%OPUSDT-1.09%WIFUSDT-0.61%IOTAUSDT-0.07%POLUSDT+0.51%AXSUSDT+0.51%EOSUSDT+0.64%FARTCOINUSDT+1.95%DYDXUSDT+2.98%GALAUSDT+0.98%ORDIUSDT+2.19%RONINUSDT+1.89%NOTUSDT+1.92%
AP

Acadia Pharmaceuticals Inc. (ACAD)

NASDAQ • Healthcare

$20.17
+$0.43 (+2.2%)
Market closed

Last close at October 27, 2026 at 20:00 UTC

Open$19.58
Day Range$19.51 - $20.29
Avg. Volume (3M)1.9M
Market Cap$3.4B
P/E Ratio9.0
52 Week Range
$18.39$30.96
Next EarningsIn 8 daysNov 4, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$307.9M100%
Gross Profitminus cost of goods$279.6M91%
Operating Incomeminus R&D and overhead$37.8M12%
Net Incomeminus taxes and the rest$31.5M10%

In plain terms: out of every $100 in revenue, Acadia Pharmaceuticals Inc. keeps $10 as net profit.

Fundamentals & Financials

Revenue (TTM)
$1.1B
Net Income (TTM)
$380.4M
EPS (TTM)
$2.25
ROA (TTM)
21.83%
Current Ratio
3.39

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+1067.9%Q1 2026$1.6
-50.0%Q2 2026$0.02
+164.1%Q3 2026$0.18
Next

Nov 4

in 8 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Beat +164.1%

ACADIA Pharmaceuticals beat expectations on both the top and bottom line in the second fiscal quarter of 2026, reported August 4, with EPS of $0.18 topping the $0.07 estimate (+164%) as revenue of $308.0 million topped the $296.6 million estimate (+3.8%). Revenue rose ~16% to about $308.0 million (up from about $264.6 million a year ago), while profitability stayed high with gross margin near 91% and operating margin around 12%, alongside operating income of roughly $37.8 million. Net income increased ~18% to about $31.5 million, compared with roughly $26.7 million a year ago, and EPS rose 12.5% from $0.16. The company generated operating cash flow of about $134.8 million during the quarter. For the next period, consensus calls for EPS of $0.20 on revenue of $332.3 million.

Next report — what to expect

ACADIA Pharmaceuticals Inc. (ACAD) is set to report earnings on November 4, 2026. Wall Street consensus calls for EPS of $0.21 on revenue of $332.1 million. For trailing context, revenue grew +16.4% year over year last quarter. ACAD has beaten EPS in 7 of 8 most recent quarters.

View full earnings history

About Acadia Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc. develops and commercializes small-molecule therapies for central nervous system disorders and operates in biotechnology within the healthcare sector. The NASDAQ-listed company trades as ACAD, and its only marketed product, NUPLAZID, helped generate $1.1 billion of revenue in FY2025.

Name
Acadia Pharmaceuticals Inc.
CEO
Catherine E. Owen Adams
Website
www.acadia.com
Industry
Healthcare
Year Founded
1993
Employees
797

Today's Snapshot

AI-generated

ACAD closed 2.2% above yesterday's close, while its sector was flat. Acadia Pharmaceuticals reported higher profit. ACAD reports earnings on 4 November.

Trading Volume

Below 10d avg (1.4M)

1.3M

vs S&P 500 Today

Outperforming Market

+1.49%

Updated: October 27, 2026 at 20:32 UTC

Technical Indicators

1 Buy3 Neutral4 Sell
ACAD shows conflicting signals with short-term averages and VWAP trading near the current price while longer-term moving averages remain above it, leaving the medium-term trend biased lower. ADX is elevated, signaling that the prevailing directional pressure favors sellers, even as momentum indicators are mixed and volatility is moderate. On-balance volume displays a buy signal despite the negative longer-term bias, suggesting pockets of accumulation amid broader weakness. Technical takeaway: Sell.
All signals
  • EMA (5 indicators)$19.95 - $23.92
    Sell
  • RSI (14)40.91
    Neutral
  • Stochastic %K (14, 3, 3)68.15
    Neutral
  • MACD Level (12, 26)-1.07
    Neutral

Peers & Related Assets

PRAXPraxis Precision Medicines, Inc.
$267.59+0.1%
AXSMAxsome Therapeutics, Inc.
$142.2-1.3%
RAPPRapport Therapeutics, Inc. Common Stock
$27.54+8.7%
MPLTMapLight Therapeutics, Inc.
$8.17+6.7%
VNDAVanda Pharmaceuticals Inc.
$3.99+1.3%
AVXLAnavex Life Sciences Corp.
$1.31+2.3%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.